1. Villa LL, Costa RR, Petta CA, Andrade R, Ault K, Giuliano A, Wheeler C, Koutsky L, Malm C, Lehtinen M: Prophylactic human papillomavirus (types 6,11,16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol. 2005, 6: 271-8. 10.1016/S1470-2045(05)70101-7.
2. Brinkman JA, Caffrey AS, Muderspach LI, Roman LD, Kast WM: The impact of anti HPV vaccination on cervical cancer incidence and HPV induced cervical lesions: consequences for clinical management. Eur J Gynaecol Oncol. 2005, XXVI: 129-142.
3. Wright TC, Van Damme P, Schmitt H-J, Meheus A: HPV vaccine introduction in industrialized countries. Vaccine. 2006, 24 (Suppl 3): S178-86.
4. Harper DM, Franco EL, Wheeler C, Ferris D, Jenkins D, Schuind A, Zahaf T, Innis B, Naud P, De Carvalho N: Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet. 2004, 364: 1757-65. 10.1016/S0140-6736(04)17398-4.
5. Advisory Committee on Immunization Practices: Provisional recommendations for the use of the quadrivalent HPV vaccine. Centers for Disease Control, Atlanta, August 14, 2006, [
http://www.cdc.gov/nip/recs/provisional_recs/hpv.pdf
]